Publications by authors named "Jessica Haug"

Claim this Profile
H
Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
Vijay G Ramakrishnan, Kevin C Miller, Elaine P Macon, Teresa K Kimlinger, Jessica Haug

Haematologica· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma.
Utkarsh Painuly, Vijay Ramakrishnan, Teresa Kimlinger, Linda Wellik, Jessica Haug

Oncotarget· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Vijay Ramakrishnan, Marcus Gomez, Vivek Prasad, Teresa Kimlinger, Utkarsh Painuly, Jessica Haug

Oncotarget· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
Vijay Ramakrishnan, Teresa Kimlinger, Michael Timm, Jessica Haug, S Vincent Rajkumar

Leuk Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway.
Vijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, Utkarsh Painuly, Linda Wellik

PLoS One· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Vijay Ramakrishnan, Michael Timm, Jessica L Haug, Teresa K Kimlinger, Timothy Halling

Am J Hematol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Shaji K Kumar, Hajime Uno, Susanna J Jacobus, Scott A Van Wier, Greg J Ahmann, Jessica L Haug

Blood· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Vijay Ramakrishnan, Teresa Kimlinger, Jessica Haug, Michael Timm, Linda Wellik

Am J Hematol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells.
Michael P Kline, S Vincent Rajkumar, Michael M Timm, Teresa K Kimlinger, Jessica L Haug

Exp Hematol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Shaji Kumar, Thomas E Witzig, Michael Timm, Jessica Haug, Linda Wellik

Blood· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma.
Michael A Thompson, Thomas E Witzig, Shaji Kumar, Michael M Timm, Jessica Haug

Br J Haematol· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis